Explore 3 Stock Ideas & Industry Insights Download Free Report

888-969-2592
Shopping Cart 0
countryflagCA
Login

Home CompaniesImmuneering Corp

Immuneering Corp

Healthcare Biotechnology
PortfolioPortfolio WatchlistWatchlist
Company price
3.68 USD 0.31 ( 9.20%)
Last update at 2026-11-06T21:00:00Z
VOLUME
681323
Market Cap
287.26M

Momentum Score

…

Immuneering Corporation, a late-stage oncology company, develops medicines for broad populations of cancer patients in the United States. The company develops IMM-1-104 (atebimetinib), a dual-MEK inhibitor that is in a Phase 3 clinical trial to treat patients with cancer, including pancreatic and non-small cell lung cancer caused by mutations of RAS or RAF; IMM-6-415 (envometinib), which is in Phase 1/2a clinical trial for the treatment of patients with solid tumors; and multiple deep cyclic inhibitor discovery programs. The company has clinical supply agreements with Regeneron Pharmaceuticals to evaluate atebimetinib in combination with Libtayo in patients with unresectable or metastatic RAS-mutant non-small cell lung cancer; and with Eli Lilly and Company to evaluate atebimetinib in combination with olomorasib in patients with advanced or metastatic KRAS G12C-mutant non-small cell lung cancer. Immuneering Corporation was incorporated in 2008 and is headquartered in Cambridge, Massachusetts.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
3.37
Low
3.70
High
52 Week Price Range
3.86
Low
10.08
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

Immuneering Corporation is a publicly listed biotechnology company focused on therapeutic discovery and development; public disclosures provide limited detail on its pipeline and technologies. Long-term growth may be supported by clinical program advancement, partnering or licensing outcomes, and broader acceptance of computational approaches in drug discovery, which could make its pipeline value-accretive for investors.
Key investment risks include clinical and regulatory failure, limited operating history and public disclosure, need for continued financing with potential dilution, and intense competition in drug development.

Risk Score
High

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
3.37
Dividend Yield
-
Revenue TTM
0.00M
Revenue Per Share
-
Gross Profit TTM
0.16M
Debt / Equity
0.02
ROE
-52.15%
Net Debt
-124.82M
ROCE
-25.25%
Diluted EPS TTM
-0.95

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax -56.02M -61.04M -53.47M -50.51M -33.84M
Net income -56.02M -61.04M -53.47M -49.28M -33.54M
Selling general administrative 17.30M 16.08M 16.76M 15.61M 8.27M
Selling and marketing expenses - - 0.51M - -
Gross profit -0.70M -0.71M -0.76M 0.16M 0.93M
Reconciled depreciation 0.35M 0.39M 0.86M 0.80M 0.16M
Ebit -56.02M -64.07M -58.41M -51.74M -34.05M
Ebitda -55.33M -63.69M -58.06M -51.71M -33.89M
Depreciation and amortization 0.70M 0.39M 0.35M 0.03M 0.16M
Non operating income net other - - - 1.25M -0.01M
Operating income -59.38M -64.07M -58.41M -51.74M -33.89M
Other operating expenses 59.38M 64.07M 58.41M 52.06M 35.97M
Interest expense - - - 1.01M 0.20M
Tax provision - - - 0.00M -0.31M
Interest income 3.04M 2.59M 3.37M 1.01M 0.17M
Net interest income 3.04M 2.59M 3.37M 1.01M 0.17M
Income tax expense - - 0.00M -1.23M -0.31M
Total revenue 0.00M 0.00M 0.00M 0.32M 2.08M
Total operating expenses 58.68M 64.07M 58.41M 51.90M 34.81M
Cost of revenue 0.70M 0.71M 0.76M 0.16M 1.15M
Total other income expense net 3.35M 3.03M 4.94M 1.23M 0.04M
Net income from continuing ops -56.02M -61.04M -51.63M -50.51M -33.54M
Net income applicable to common shares - - - -50.51M -33.54M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 231.99M 52.71M 102.58M 122.37M 166.70M
Intangible assets 0.32M 0.35M 0.38M 0.41M 0.44M
Other current assets 3.41M 3.44M 3.42M 3.21M 2.89M
Total liab 13.50M 11.33M 12.01M 12.52M 10.72M
Total stockholder equity 218.48M 41.39M 90.58M 109.85M 155.98M
Other current liab 8.13M 5.21M 0.26M 4.52M 3.97M
Common stock 0.06M 0.03M 0.03M 0.03M 0.03M
Capital stock 0.06M 0.03M 0.03M 0.03M 0.03M
Retained earnings -280.32M -224.30M -163.26M -109.79M -59.27M
Good will 6.69M 6.69M 6.69M 6.69M 6.70M
Other assets - 0.00M - 0.74M 0.10M
Cash 128.65M 36.14M 59.41M 72.64M 74.89M
Total current liabilities 10.07M 7.50M 7.85M 8.05M 5.63M
Current deferred revenue - - 5.17M - -
Net debt -124.82M -31.98M -54.94M -67.80M -69.52M
Short term debt 0.40M 0.34M 0.30M 0.38M 0.27M
Short long term debt total 3.82M 4.16M 4.46M 4.84M 5.36M
Other stockholder equity 498.66M 265.65M 253.81M -122147.64M -166489.56M
Property plant equipment - - - 1.37M 0.81M
Total current assets 176.25M 39.59M 89.08M 108.75M 152.33M
Long term investments 44.18M 0.00M - 0.00M 1.00M
Net tangible assets - - - 109.85M 155.98M
Short term investments 44.19M -36108.58M 26.26M 32.89M 74.31M
Net receivables - - 0.00M 0.01M 0.25M
Inventory - - - - -74.31M
Accounts payable 1.54M 1.96M 2.11M 3.15M 1.39M
Accumulated other comprehensive income 0.08M - -0.00M -0.03M -0.05M
Common stock total equity - - - 0.03M 0.03M
Retained earnings total equity - - - -109.79M -59.27M
Non currrent assets other 0.28M 1.30M 1.03M 0.74M 0.10M
Non current assets total 55.74M 13.13M 13.50M 13.62M 14.37M
Capital lease obligations 3.82M 4.16M 4.46M 4.84M 5.36M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments -88.60M 26.43M 12.32M 42.57M -75.63M
Change to liabilities - - - 2.25M 3.11M
Total cashflows from investing activities -88.74M 26.43M 7.30M 41.83M -75.62M
Total cash from financing activities 226.58M 5.30M 28.44M 0.02M 144.26M
Change to operating activities - - - -0.28M 0.75M
Net income -56.02M -61.04M -53.47M -50.51M -33.54M
Change in cash 92.50M -23.26M -13.23M -2.25M 37.80M
Begin period cash flow 36.14M 59.41M 72.64M 74.89M 37.09M
End period cash flow 128.65M 36.14M 59.41M 72.64M 74.89M
Total cash from operating activities -45.34M -55.00M -48.97M -44.10M -30.85M
Issuance of capital stock 229.52M 4.24M 28.20M 0.00M 145.11M
Depreciation 0.35M 0.39M 0.35M 0.80M 0.16M
Other cashflows from investing activities 0.00M 26.43M - - 0.07M
Change to account receivables - 0.00M 0.01M 0.23M 0.28M
Sale purchase of stock - - - 0.02M 144.26M
Other cashflows from financing activities -3.73M 1.07M 0.24M 0.02M 23.95M
Change to netincome - - - 4.07M 1.50M
Capital expenditures 0.14M 0.08M 0.34M 0.74M 0.06M
Change receivables - - - 0.23M 0.28M
Cash flows other operating - - - -0.25M -2.38M
Cash and cash equivalents changes - - - -2.25M 37.80M
Change in working capital 3.82M -0.93M -0.97M 1.72M 0.90M
Stock based compensation 6.31M 6.50M 5.73M 4.06M 1.80M
Other non cash items 0.19M 0.08M -0.60M -0.17M 0.13M
Free cash flow -45.49M -55.08M -49.31M -44.84M -30.91M

Peer Comparison*

Sector: Healthcare Industry: Biotechnology

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
IMRX
Immuneering Corp		 0.31
9.20%		 3.68 - - 563.62 1.47 191913.54 -1.53
NVO
Novo Nordisk A/S		 0.01
0.02%		 40.31 41.58 31.15 2.13 32.99 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 4.59
0.85%		 547.09 30.22 24.27 10.36 6.50 9.99 24.66
REGN
Regeneron Pharmaceuticals Inc		 1.45
0.16%		 904.35 29.07 20.12 7.57 3.82 6.95 19.42
ARGNF
argenx SE		 -
-%		 900.30 45.77 31.25 13.84 7.12 11.38 36.06

Profile*

Immuneering Corp

Immuneering Corporation, a late-stage oncology company, develops medicines for broad populations of cancer patients in the United States. The company develops IMM-1-104 (atebimetinib), a dual-MEK inhibitor that is in a Phase 3 clinical trial to treat patients with cancer, including pancreatic and non-small cell lung cancer caused by mutations of RAS or RAF; IMM-6-415 (envometinib), which is in Phase 1/2a clinical trial for the treatment of patients with solid tumors; and multiple deep cyclic inhibitor discovery programs. The company has clinical supply agreements with Regeneron Pharmaceuticals to evaluate atebimetinib in combination with Libtayo in patients with unresectable or metastatic RAS-mutant non-small cell lung cancer; and with Eli Lilly and Company to evaluate atebimetinib in combination with olomorasib in patients with advanced or metastatic KRAS G12C-mutant non-small cell lung cancer. Immuneering Corporation was incorporated in 2008 and is headquartered in Cambridge, Massachusetts.

245 Main Street, Cambridge, MA, United States, 02142

617 500 8080

https://immuneering.com

57

Name Title Year Born
Dr. Benjamin J. Zeskind M.B.A., MBA, Ph.D. Co-Founder, Pres, CEO & Director 1983
Dr. Brett M. Hall Ph.D. Chief Scientific Officer 1968
Ms. Mallory Morales CPA VP of Fin., Principal Financial & Accounting Officer and Treasurer 1983
Ms. Paula George CPA Sr. Mang. of Accounting & Operations NA
Mr. Michael D. Bookman J.D. Gen. Counsel & Sec. 1988
Ms. Leah R. Neufeld Chief People Officer NA
Dr. Scott Barrett M.D. Chief Medical Officer 1963
Dr. Mohamedi Kagalwala M.B.A., Ph.D. Head of Neuroscience Devel. NA
Dr. Peter King Ph.D. Head of Discovery & VP NA
Dr. Rajaraman Krishnan Ph.D. Head of Neuroscience Discovery NA

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

ITH
CAD 2.15
+27.68%
HG
CAD 4.11
+19.13%
PPTA
CAD 27.74
+17.99%
UCU
CAD 2.10
+17.32%
GAU
CAD 3.49
+16.72%
TSU
CAD 29.67
-29.71%
PXT
CAD 19.73
-16.91%
LAS-A
CAD 230.50
-9.25%
IFP
CAD 13.50
-8.35%
NFI
CAD 24.01
-7.80%

Equity Sectors*

  • Basic Materials

    +3.74%

  • Communication Services

    +0.56%

  • Consumer Cyclical

    -0.34%

  • Consumer Defensive

    +0.11%

  • Energy

    +1.33%

  • Financial Services

    -0.26%

  • Healthcare

    +2.54%

  • Industrials

    -0.11%

  • Real Estate

    -0.23%

  • Technology

    +1.91%

  • Utilities

    +1.05%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…